The aggregate gross proceeds to the Company from the offering were approximately $1,050,000, before deducting the placement ...

The IT workforce reductions come as Moderna’s chief information officer Brad Miller departs after a two-year stint. Story Feb. 13 - Encoded Therapeutics: The gene therapy biotech is laying off ...

Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...

New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of ...

February 13, 2025 - Dr. Pardeep Nijhawan (“Dr. Nijhawan”) and Velan Capital jointly announce updates to their beneficial ownership of securities of Edesa Biotech, Inc. (“Edesa”) in accordance with ...

"TGFB2 has emerged as a master regulator of immune suppression, not just in cancer but across multiple chronic diseases,” said Dr. Trieu. "Our work on OT-101 aims to neutralize TGFB2-driven resistance ...

LONDON - Allergy Therapeutics plc (AIM: AGY), a commercial biotechnology company specializing in allergy vaccines, has granted share options to select members of its management team, including certain ...

Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...

In this post, I will focus on how companies around the world, and in different sectors, performed on their end game of ...